Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors associated with urinary tract infection within 4 days of male rectal cancer surgery in the era of enhanced recovery after surgery (ERAS) programs.

Acta chirurgica Belgica·2026
Same author

Evidences That Host Genetic Background More Than the Environment Shapes the Microbiota of the Snail Bulinus truncatus, an Intermediate Host of Schistosoma Species.

Molecular ecology·2026
Same author

Host genetic background influences the severity of disease in Schistosoma haematobium infections.

Parasite (Paris, France)·2026
Same author

Thiophene-based styrene derivative improves colitis symptoms in DSS-induced BALB/C mice through AhR-mediated gut barrier function and inflammatory responses.

Toxicology and applied pharmacology·2026
Same author

African zoonotic schistosomiasis: a paradigm shift.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same author

Transcriptomic plasticity in hybrid schistosomes can contribute to their zoonotic potential.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026

Related Experiment Video

Updated: May 10, 2026

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

Schistosomiasis chemotherapy.

Sophie A-L Thétiot-Laurent1, Jérôme Boissier, Anne Robert

  • 1Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, BP 44099, 31077 Toulouse cedex 4, France.

Angewandte Chemie (International Ed. in English)
|July 2, 2013
PubMed
Summary

Schistosomiasis is a major parasitic disease affecting millions globally. New drugs are urgently needed to combat praziquantel resistance and develop effective combination therapies.

Keywords:
artemisinindrugspraziquantelschistosomiasistrioxaquine

More Related Videos

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni
12:05

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
09:58

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

Related Experiment Videos

Last Updated: May 10, 2026

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni
12:05

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
09:58

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

Area of Science:

  • Neglected Tropical Diseases
  • Parasitology
  • Drug Discovery

Background:

  • Schistosomiasis (bilharzia) is the second most prevalent parasitic disease in Africa, impacting over 70 countries.
  • An estimated 200 million people are infected, with at least 200,000 annual deaths, and 600 million at risk.
  • Transmission occurs through freshwater contact with cercariae, the free-swimming parasite stage.

Purpose of the Study:

  • To highlight the urgent need for novel antischistosomal drugs.
  • To emphasize the development of new therapies to be combined with praziquantel for bitherapy.
  • To address the growing concern over reduced praziquantel efficacy.

Main Methods:

  • Literature review on schistosomiasis prevalence and treatment limitations.
  • Analysis of current antischistosomal drug arsenal and its shortcomings.
  • Discussion on the necessity of new drug development strategies.

Main Results:

  • Current treatment relies solely on praziquantel, used for over 35 years.
  • Vaccine candidates have thus far been unsuccessful.
  • Concerns regarding praziquantel's diminishing activity necessitate new therapeutic approaches.

Conclusions:

  • There is a critical need for new, safe antischistosomal drugs.
  • Developing combination therapies (bitherapies) with praziquantel is essential.
  • Urgent research and development are required to combat schistosomiasis effectively.